Indegene Limited announced the resignation of Mark Francis Dzialga from its Board of Directors, effective October 29, 2026. The departure follows the sale of the entire shareholding in the company held by Brighton Park Capital and its affiliated investment vehicles.

Dzialga served as a Non-Executive Non-Independent Director. His resignation letter, dated October 14, 2026, confirmed that he is leaving due to the divestment of shares by his affiliated firm. He explicitly stated that the resignation is not on account of any disagreement with the company regarding operations or corporate governance standards.

Board committee changes

Upon cessation of his role as a director, Dzialga will also cease to be a member of two key board committees. This change in composition is reported under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The committees affected are:

• Nomination and Remuneration Committee
• Investment Committee

Regulatory disclosures

Indegene filed the intimation with BSE and NSE on October 15, 2026. The disclosure includes details mandated by the SEBI Master Circular dated January 30, 2026. Dzialga confirmed there are no other material reasons for his resignation other than those mentioned in his letter.

Governance implications

The exit of a director linked to a major institutional investor often signals a shift in shareholder structure. Brighton Park Capital's complete sale of its stake removes a significant institutional presence from the register of shareholders. While the company stated no operational disagreements exist, the removal of an investor-nominated director alters the board's composition and potentially its investment oversight dynamics.

Indegene Limited hosted its Digital Summit 2026 at the National Constitution Center in Philadelphia on September 22, 2026. The event gathered 120+ senior life sciences leaders to discuss the transition from AI experimentation to enterprise-scale operationalization.

The summit featured 19 speakers, representing a 40% increase in pharma participation compared to the previous year. Attendees included commercial, medical, digital, and technology executives from major pharmaceutical companies and emerging biopharma firms. The agenda focused on shifting industry conversations from theoretical AI capabilities to measurable business performance and governance.

Keynote sessions and strategic themes

Keynote addresses were delivered by prominent industry figures, including David Shulkin, former Secretary of the U.S. Department of Veterans Affairs; Amol Punjabi, Chief Product Officer at OpenEvidence; Agam Upadhyay, Chief Digital and Information Officer at Vertex; and Corinne Le Goff, Chief Commercial Officer at Viatris. These sessions highlighted the critical role of domain expertise in an AI-native world and the necessity of reimagined operating models.

The summit emphasized that AI success depends on workflow redesign and business ownership rather than technology alone. Sessions explored topics such as point-of-care AI, customer engagement models for 2028, and the transformation of mature brands into innovation engines. Indegene’s CTO, Tarun Mathur, noted that expert knowledge dramatically improves agent performance, shifting experts from creators to reviewers.

Interactive experience zones

Indegene introduced an integrated AI Experience Zone, moving beyond isolated capability kiosks of previous years. This zone offered a connected client journey across strategy, content, and engagement through three core experiences:

1. Imagine at Speed: Powered by Agentic AOR, turning brand intelligence into campaign-ready concepts.
2. Create at Scale: Powered by Content Super App, transforming hero ideas into compliant, channel-ready experiences.
3. Engage with Precision: Powered by Audience IQ (Tandem), using audience signals to shape next-best experiences.

Vital Awards recognition

The event concluded with the Vital Awards, recognizing leaders driving measurable impact across healthcare. Six awardees were honored for their contributions to digital transformation and commercial excellence:

What the Numbers Show

The summit data reveals a strategic pivot in audience composition and engagement depth. With 50% of attendees identified as decision-makers and 70% holding Director-level or higher positions, the event successfully targeted high-influence stakeholders. The 40% year-on-year increase in pharma speaker participation indicates growing industry trust in Indegene as a convenor for peer-to-peer exchange, reinforcing its position not just as a service provider but as a strategic partner in enterprise AI adoption.